

Accepted Manuscript



Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks' gestation

Andreas Tsiakkas, M.D., Youssef Saiid, M.D., Alan Wright, PhD., David Wright, PhD., Kypros H. Nicolaides, M.D.

PII: S0002-9378(16)00300-8

DOI: [10.1016/j.ajog.2016.02.016](https://doi.org/10.1016/j.ajog.2016.02.016)

Reference: YMOB 10936

To appear in: *American Journal of Obstetrics and Gynecology*

Received Date: 16 October 2015

Revised Date: 14 November 2015

Accepted Date: 5 February 2016

Please cite this article as: Tsiakkas A, Saiid Y, Wright A, Wright D, Nicolaides KH, Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks' gestation, *American Journal of Obstetrics and Gynecology* (2016), doi: 10.1016/j.ajog.2016.02.016.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks' gestation

Andreas TSIKKAS, M.D.,¹ Youssef SAIID, M.D.,¹ Alan WRIGHT, PhD.,² David WRIGHT, PhD.,² Kypros H. NICOLAIDES, M.D.¹

1. Harris Birthright Research Centre for Fetal Medicine, King's College, London, UK.
2. Institute of Health Research, University of Exeter, Exeter, UK.

Correspondence: Professor KH Nicolaides, Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, Denmark Hill, London SE5 9RS, UK.
Tel: 00 44 2032998256, email: kypros@fetalmedicine.com

Conflict of interest statement: The authors report no conflict of interest.

Sources of Funding: The study was supported by grants from the Fetal Medicine Foundation (Charity No: 1037116) and by the European Union 7th Framework Programme - FP7-HEALTH-2013-INNOVATION-2 (ASPRE Project # 601852). The reagents and equipment for the measurement of serum placental growth factor and soluble fms-like tyrosine kinase-1 were provided by Roche Diagnostics Limited.

Previous presentations: None

Download English Version:

<https://daneshyari.com/en/article/6143761>

Download Persian Version:

<https://daneshyari.com/article/6143761>

[Daneshyari.com](https://daneshyari.com)